• 1
    Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998; 16: 24452451.
  • 2
    Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related KS. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998; 16: 683691.
  • 3
    Gill PS, Wernz J, Scadden DT, et al. Randomized phase III study of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related KS. J Clin Oncol. 1996; 14: 23532364.
  • 4
    Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. 1999; 6: 18761883.
  • 5
    Boue F, Zaikas G, Lancar R, et al. Activity of Taxotere (docetaxel) as therapy for pretreated HIV-associated Kaposi's sarcoma (KS): an ANRS trial [abstract 182],. Proc Am Soc Clin Oncol 1998; 17: 47a.
  • 6
    Hainsworth JD, Burris HA 3rd, Yardley DA. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. 2001; 15: 35003505.
  • 7
    Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma and the acquired immunodeficiency syndrome: a proposal for a uniform evaluation, response and staging criteria. J Clin Oncol. 1989; 7: 12011207.
  • 8
    Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant mullerian carcinoma. J Clin Oncol. 2000; 14: 27332739.
  • 9
    Valero V, Jones SE, Von Hoff DD, et al: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998; 16: 33623368.
  • 10
    Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS. 1998; 12: F45F49.
  • 11
    Diz Dios P, Ocampo Hermida A, Miralles Alvarez C,et al. Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy. Oral Oncol. 1998; 34: 236238.
  • 12
    Minisini AM, Tosti A, Sobrero AF, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003; 2: 333337.
  • 13
    Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ. 1999; 319: 2324.
  • 14
    Herida M, Mary-Krause M, Kaphan R, et al. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000; 92: 18231830.
  • 15
    Jones JL, Hanson DL, Dworkin MS, et al. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr. 2000; 3: 270274.